Cover Image
市場調查報告書

PharmaPoint:腎細胞癌 (RCC) - 全球醫藥品市場預測與市場分析

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 364823
出版日期 內容資訊 英文 322 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:腎細胞癌 (RCC) - 全球醫藥品市場預測與市場分析 PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
出版日期: 2016年04月21日 內容資訊: 英文 322 Pages
簡介

本報告提供腎細胞癌 (RCC) 治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊,SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 病期分類
  • 症狀
  • 預後模式
  • 潛在的生物標記

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
    • 發病率
    • RCC的存活率:8MM
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:發病數量
    • 預測的前提條件與手法:5年的患病數量
    • 預測的前提條件與手法:診斷時的臨床階段
  • 流行病學預測
    • 確診的發病數量
    • 各年齡的發病數量
    • 性別的發病數量
    • 標準化了年齡的發病數量
    • 各診斷時臨床階段的發病數量
    • 5年的患病數量
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷、治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國

第6章 競爭評估

  • 概要
  • 藥物簡介:領導品牌
    • Sutent (sunitinib)
    • Nexavar (sorafenib)
    • Votrient (pazopanib)
    • Avastin (bevacizumab)
    • Torisel (temsirolimus)
    • Inlyta (axitinib)
    • Afinitor (everolimus)
    • Interferon-alfa
    • Interleukin-2
    • Tarceva (erlotinib)

第7章 未滿足需求和機會

  • 概要

第8章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
    • divo (nivolumab) 、 Yervoy (ipilimumab)
    • Atezolizumab
    • Cometriq (cabozantinib)
    • IMA901
    • AGS-003(rocapuldencel-t)
    • Tivozanib
    • Lenvima (lenvatinib)
    • Avelumab

第9章 初期開發階段的有潛力方法

  • Keytruda (pembrolizumab)
  • Dalantercept (ACE-041)
  • Archexin (RX-021)
  • 其他開發中的藥物

第10章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Pfizer
    • Novartis
    • Bayer
    • Roche
    • Bristol-Myers Squibb
    • Merck & Co.
    • Exelixis
    • Eisai
    • AVEO Oncology
    • Argos Therapeutics

第11章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本
  • 中國

第12章 附錄

圖表

目錄
Product Code: GDHC88PIDR

Renal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market is currently dominated by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in particular, but it will experience dramatic changes over the forecast period as patents expire and promising new therapies enter the market. A large share of the RCC market is currently dominated by a few large companies, but they will struggle to retain these shares as they are joined by new entrants. One of these new entrants, Opdivo, is expected to have the largest market share by 2023. The different lines of treatment will offer up different battlegrounds and niches for companies, large and small, to compete for. The battle for the first-line of therapy is expected to be fierce, with three programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1)-containing combination therapies backed by large companies lining up to compete. Out of this competition, new standards of care are expected to emerge for the different lines of treatment. There will also be a number of unmet needs still remaining at the end of the forecast period, and with that, the opportunity for pipeline drugs to carve out a niche in the RCC space.

Highlights

Key Questions Answered

  • The RCC market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of RCC market?
  • The late-stage RCC pipeline has therapies targeting different lines of therapy. Which drugs will have the biggest impact in each RCC setting? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • Current therapies used to treat RCC include tyrosine kinase inhibitors and mTOR inhibitors. What will be the impact of the patent expiry of the current standard of care? How will the advent of new therapies change the drug treatment landscape for RCC? How will new drug combinations change the treatment paradigm of RCC? What are the key drivers and barriers to this change?

Key Findings

  • The main drivers of the growth of the RCC market will be the launch of Opdivo in second-line setting and PD-1 modulator combinations in the first-line setting. GlobalData forecasts significant patient uptake for Opdivo, which will supersede tyrosine kinase inhibitors and mTOR inhibitors to become the SoC in second-line setting.
  • The approval of immunotherapy in monotherapy or in combination with other agents will partially fulfil key unmet needs in the RCC space: however, many of these unmet needs will still remain even after these agents are launched.
  • Another driver of the RCC market is the increasing incidence of RCC cases within the 8MM. The biggest constrainer of the RCC market is the launch of generics of tyrosine kinase inhibitors currently established as standard of care in most markets.

Scope

  • Overview of RCC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized RCC therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the RCC therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global RCC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global RCC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RCC therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global RCC therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Clinical Staging
  • 3.3. Symptoms
  • 3.4. Prognostic Models
  • 3.5. Potential Biomarkers

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. Incidence
    • 4.3.2. Survival Rates for RCC - 8MM
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods for RCC Diagnosed Incident Cases
    • 4.4.4. Forecast Assumptions and Methods for RCC Five-Year Diagnosed Prevalent Cases
    • 4.4.5. Forecast Assumptions and Methods for RCC by Clinical Stage at Diagnosis
  • 4.5. Epidemiological Forecast of RCC (2013-2023)
    • 4.5.1. Diagnosed Incident Cases of RCC
    • 4.5.2. Age-Specific Diagnosed Incident Cases of RCC
    • 4.5.3. Sex-Specific Diagnosed Incident Cases of RCC
    • 4.5.4. Age-Standardized Diagnosed Incidence of RCC
    • 4.5.5. Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis
    • 4.5.6. Five-Year Diagnosed Prevalent Cases of RCC
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Screening and Diagnosis
    • 5.1.2. Surgical Management of RCC
    • 5.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.4. Clinical Practice
  • 5.2. US
    • 5.2.1. Diagnosis and Surgical Management
    • 5.2.2. Clinical Practice (Drug Treatment)
  • 5.3. France
    • 5.3.1. Diagnosis and Surgical Management
    • 5.3.2. Clinical Practice (Drug Treatment)
  • 5.4. Germany
    • 5.4.1. Diagnosis and Surgical Management
    • 5.4.2. Clinical Practice (Drug Treatment)
  • 5.5. Italy
    • 5.5.1. Diagnosis and Surgical Management
    • 5.5.2. Clinical Practice (Drug Treatment)
  • 5.6. Spain
    • 5.6.1. Diagnosis and Surgical Management
    • 5.6.2. Clinical Practice (Drug Treatment)
  • 5.7. UK
    • 5.7.1. Diagnosis and Surgical Management
    • 5.7.2. Clinical Practice (Drug Treatment)
  • 5.8. Japan
    • 5.8.1. Diagnosis and Surgical Management
    • 5.8.2. Clinical Practice (Drug Treatment)
  • 5.9. China
    • 5.9.1. Diagnosis and Surgical Management
    • 5.9.2. Clinical Practice (Drug Treatment)

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Sutent (sunitinib)
    • 6.2.2. Nexavar (sorafenib)
    • 6.2.3. Votrient (pazopanib)
    • 6.2.4. Avastin (bevacizumab)
    • 6.2.5. Torisel (temsirolimus)
    • 6.2.6. Inlyta (axitinib)
    • 6.2.7. Afinitor (everolimus)
    • 6.2.8. Interferon-alfa
    • 6.2.9. Interleukin-2
    • 6.2.10. Tarceva (erlotinib)

7. Unmet Needs and Opportunities

  • 7.1. Overview
  • 7.2. Challenge the Resistance to Metastatic RCC Treatments With New Targeted Agents Improving the Survival of Metastatic RCC Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Drugs With Improved Tolerability Profiles
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. More Efficacious Therapies for the Treatment of Unfavorable Risk Metastatic RCC
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Targeted Therapies for Non-Clear Cell RCC
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Novel Adjuvant Therapies for Non-Metastatic RCC
    • 7.6.1. Unmet need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Biomarkers
    • 7.7.1. Overview
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Opdivo (nivolumab) and Yervoy (ipilimumab)
    • 8.2.2. Atezolizumab
    • 8.2.3. Cometriq (cabozantinib)
    • 8.2.4. IMA901
    • 8.2.5. AGS-003(rocapuldencel-t)
    • 8.2.6. Tivozanib
    • 8.2.7. Lenvima (lenvatinib)
    • 8.2.8. Avelumab

9. Promising Approaches in Early-Stage Development

  • 9.1. Keytruda (pembrolizumab)
    • 9.1.1. Overview
  • 9.2. Dalantercept (ACE-041)
    • 9.2.1. Overview
  • 9.3. Archexin (RX-021)
    • 9.3.1. Overview
  • 9.4. Other Drugs in Development

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Pfizer
    • 10.3.2. Novartis
    • 10.3.3. Bayer
    • 10.3.4. Roche
    • 10.3.5. Bristol-Myers Squibb
    • 10.3.6. Merck & Co.
    • 10.3.7. Exelixis
    • 10.3.8. Eisai
    • 10.3.9. AVEO Oncology
    • 10.3.10. Argos Therapeutics

11. Market Outlook

  • 11.1. Global Markets
    • 11.1.1. Forecast
    • 11.1.2. Drivers and Barriers - Global Issues
  • 11.2. US
    • 11.2.1. Forecast
    • 11.2.2. Key Events
    • 11.2.3. Drivers and Barriers
  • 11.3. 5EU
    • 11.3.1. Forecast
    • 11.3.2. Key Events
    • 11.3.3. Drivers and Barriers
  • 11.4. Japan
    • 11.4.1. Forecast
    • 11.4.2. Key Events
    • 11.4.3. Drivers and Barriers
  • 11.5. China
    • 11.5.1. Forecast
    • 11.5.2. Key Events
    • 11.5.3. Drivers and Barriers

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Methodology
  • 12.4. Forecasting Methodology
    • 12.4.1. Diagnosed RCC Patients
    • 12.4.2. Percent Drug-Treated Patients
    • 12.4.3. Drugs Included in Each Therapeutic Class
    • 12.4.4. Launch and Patent Expiration Dates
    • 12.4.5. General Pricing Assumptions
    • 12.4.6. Average Body Weight and Surface Area Across the 8MM
    • 12.4.7. General Forecast Assumptions
    • 12.4.8. Individual Drug Assumptions
    • 12.4.9. Generic Erosion
    • 12.4.10. Pricing of Pipeline Agents
  • 12.5. Primary Research - KOLs Interviewed for This Report
  • 12.6. Primary Research - High-Prescribers Surveyed for this Report
  • 12.7. About the Authors
    • 12.7.1. Author
    • 12.7.2. Epidemiologist
    • 12.7.3. Therapy Director
    • 12.7.4. Global Director of Therapy Analysis and Epidemiology
    • 12.7.5. Global Head of Healthcare
  • 12.8. About GlobalData
  • 12.9. Disclaimer

List of Tables

  • Table 1: Classifications of RCC
  • Table 2: TNM and Staging Classification System for RCC
  • Table 3: Symptoms of RCC
  • Table 4: Risk Factors and Comorbidities for RCC
  • Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages ≥20 Years, 1993-2007
  • Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages ≥20 Years, 1993-2007
  • Table 7: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages ≥20 Years, 1993-2007
  • Table 8: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages ≥20 Years, 1993-2007
  • Table 9: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2007
  • Table 10: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases
  • Table 11: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases
  • Table 12: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis
  • Table 13: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 14: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013
  • Table 15: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N (Row %), 2013
  • Table 16: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 17: Treatment Guidelines for RCC
  • Table 18: Most Prescribed Drugs for RCC by Class in the 8MM
  • Table 19: Country Profile - US
  • Table 20: Country Profile - France
  • Table 21: Country Profile - Germany
  • Table 22: Country Profile - Italy
  • Table 23: Country Profile - Spain
  • Table 24: Country Profile - UK
  • Table 25: Country Profile - Japan
  • Table 26: Country Profile - China
  • Table 27: Leading Treatments for RCC, 2015
  • Table 28: Product Profile - Sutent (sunitinib)
  • Table 29: Results of the Trial Comparing Sutent Versus IFN-alfa
  • Table 30: Summary of AEs from the Trial of Sutent Versus IFN-alfa
  • Table 31: Sutent SWOT Analysis, 2014
  • Table 32: Global Sales Forecasts ($m) for Sutent 2013-2023
  • Table 33: Product Profile - Nexavar (sorafenib)
  • Table 34: Results of the Trial Comparing Nexavar Versus Placebo
  • Table 35: Summary of AEs from the Trial of Nexavar versus Placebo
  • Table 36: Nexavar SWOT Analysis, 2014
  • Table 37: Global Sales Forecast ($m) for Nexavar, 2013-2023
  • Table 38: Product Profile - Votrient (pazopanib)
  • Table 39: Results of the Trial Comparing Votrient Versus Placebo
  • Table 40: Summary of the Results of the Trials Comparing Votrient Versus Sutent
  • Table 41: Summary of AEs from the Trial of Votrient Versus Sutent
  • Table 42: Votrient SWOT Analysis, 2014
  • Table 43: Global Sales Forecast ($m) for Votrient, 2013-2023
  • Table 44: Product Profile - Avastin (bevacizumab)
  • Table 45: Results of the Trial Comparing Avastin + IFN-alfa Versus IFN-alfa + Placebo
  • Table 46: Summary of AEs from the Trial of Avastin + IFN-alfa Versus IFN-alfa + placebo
  • Table 47: Avastin SWOT Analysis, 2014
  • Table 48: Global Sales Forecasts ($m) for Avastin, 2013-2023
  • Table 49: Product Profile - Torisel (temsirolimus)
  • Table 50: Results of the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa
  • Table 51: Summary of AEs from the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa
  • Table 52: Torisel SWOT Analysis, 2014
  • Table 53: Global Sales Forecasts ($m) for Torisel, 2013-2023
  • Table 54: Product Profile - Inlyta (axitinib)
  • Table 55: Results of the Trial Comparing Inlyta Versus Nexavar
  • Table 56: Summary of AEs from the Trial Comparing Inlyta Versus Nexavar
  • Table 57: Inlyta SWOT Analysis, 2014
  • Table 58: Global Sales Forecasts ($m) for Inlyta, 2013-2023
  • Table 59: Product Profile - Afinitor (everolimus)
  • Table 60: Results of the Record-1 Trial Comparing Afinitor Versus Placebo
  • Table 61: Summary of AEs from the Trial Comparing Afinitor Versus Placebo

Table 62: Afinitor SWOT Analysis

  • Table 63: Global Sales Forecasts ($m) for Afinitor, 2013-2023
  • Table 64: Results of the Trial Comparing IFN-alfa Versus IFN-alfa + vinblastine
  • Table 65: Summary of AEs from the Trial of IFN-alfa
  • Table 66: Results of the Trial Comparing High-Dose IL-2 Versus IL-2 + IFN-alfa
  • Table 67: Summary of AEs from the High-Dose IL-2 Versus IL-2 + IFN-alfa Trial
  • Table 68: Selected placebo-controlled, randomized adjuvant RCC trials
  • Table 69: Comparison of Therapeutic Classes in Development for RCC, 2016
  • Table 70: Product Profile - Opdivo (nivolumab)
  • Table 71: Product Profile - Yervoy (imilimumab)
  • Table 72: Efficacy of Opdivo in the CheckMate 025 Trial
  • Table 73: Efficacy of Opdivo + Yervoy, Opdivo + Stutent, and Opdivo + Votrient
  • Table 74: Safety of Opdivo and Afinitor from the CheckMate 025 Trial
  • Table 75: Safety Profile of Opdivo + Yervoy, Opdivo + Sutent, and Opdivo + Votrient
  • Table 76: Opdivo (monotherapy or combination with Yervoy) SWOT Analysis, 2016
  • Table 77: Global Sales Forecasts ($M) for Opdivo, 2013-2023
  • Table 78: Product Profile - Atezolizumab
  • Table 79: Efficacy of Atezolizumab
  • Table 80: Efficacy of Atezolizumab + Avastin combination therapy
  • Table 81: Safety of Atezolizumab in Phase Ib Study
  • Table 82: Atezolizumab SWOT Analysis, 2016
  • Table 83: Global Sales Forecasts ($M) for Atezolizumab, 2013-2023
  • Table 84: Product Profile - Cometriq (cabozantinib)
  • Table 85: Efficacy of Cometriq in the Phase III METEOR Trial
  • Table 86: Safety of Cometriq
  • Table 87: Cometriq SWOT Analysis, 2016
  • Table 88: Global Sales Forecasts ($M) for Cometriq, 2013-2023
  • Table 89: Product Profile - IMA901
  • Table 90: Efficacy of IMA901 in the Phase III IMPRINT Trial
  • Table 91: Product Profile - AGS-003
  • Table 92: AGS-003 SWOT Analysis, 2016
  • Table 93: Global Sales Forecasts ($M) for AGS-003, 2013-2023
  • Table 94: Product Profile - Tivozanib
  • Table 95: Efficacy of Tivozanib
  • Table 96: Safety of Tivozanib
  • Table 97: Safety profile of Tivozanib over time
  • Table 98: Tivozanib SWOT Analysis, 2016
  • Table 99: Global Sales Forecasts ($M) for Tivozanib, 2013-2023
  • Table 100: Product Profile - Lenvima (lenvatinib)
  • Table 101: Efficacy of Lenvima
  • Table 102: Lenvima SWOT Analysis, 2016
  • Table 103: Global Sales Forecasts ($M) for Lenvima, 2013-2023
  • Table 104: Product Profile - Avelumab
  • Table 105: Avelumab (in combination with Inlyta) SWOT Analysis, 2016
  • Table 106: Global Sales Forecasts ($M) for Avelumab, 2013-2023
  • Table 107: Drug Candidates in Early Development, 2016
  • Table 108: Key Companies in the RCC Market in the 8MM, 2013-2023
  • Table 109: Pfizer's RCC Portfolio Assessment, 2016
  • Table 110: Novartis' RCC Portfolio Assessment, 2016
  • Table 111: Bayer's RCC Portfolio Assessment, 2016
  • Table 112: Roche's RCC Portfolio Assessment, 2016
  • Table 113: BMS' RCC Portfolio Assessment, 2016
  • Table 114: Merck & Co.'s RCC Portfolio Assessment, 2016
  • Table 115: Exelixis' RCC Portfolio Assessment, 2016
  • Table 116: Eisai RCC Portfolio Assessment, 2016
  • Table 117: AVEO Oncology's RCC Portfolio Assessment, 2016
  • Table 118: Argos Therapeutics' RCC Portfolio Assessment, 2016
  • Table 119: Sales Forecasts ($m) for Renal Cell Carcinoma in the Global Markets, 2013-2023
  • Table 120: RCC Market Drivers and Barriers, 2013-2023
  • Table 121: Sales Forecasts ($m) for Renal Cell Carcinoma in the United States, 2013-2023
  • Table 122: Key Events Impacting Sales for RCC in the US, 2016
  • Table 123: US RCC Market Drivers and Barriers, 2016
  • Table 124: Sales Forecasts ($m) for Renal Cell Carcinoma in 5EU, 2013-2023
  • Table 125: Key Events Impacting Sales for RCC in 5EU, 2016
  • Table 126: 5EU RCC Market Drivers and Barriers, 2016
  • Table 127: Sales Forecasts ($m) for Renal Cell Carcinoma in Japan, 2013-2023
  • Table 128: Key Events Impacting Sales for RCC in Japan, 2016
  • Table 129: Japan RCC Market - Drivers and Barriers, 2016
  • Table 130: Sales Forecasts ($m) for Renal Cell Carcinoma in China, 2013-2023
  • Table 131: Key Events Impacting Sales for RCC in China, 2016
  • Table 132: China RCC Market - Drivers and Barriers, 2016
  • Table 133: RCC Incidence, 2013-2023
  • Table 134: RCC, Key Launch Dates
  • Table 135: RCC, Key Patent Expiries
  • Table 136: Average Body Weight and Surface Area Across the 8MM
  • Table 137: Average Cost of Therapy of Sutent
  • Table 138: Average Cost of Therapy of Votrient
  • Table 139: Average Cost of Therapy of Nexavar
  • Table 140: Average Cost of Therapy of Avastin
  • Table 141: Average Cost of Therapy of Inlyta
  • Table 142: Average Cost of Therapy of Torisel
  • Table 143: Average Cost of Therapy of Afinitor
  • Table 144: Average Cost of Therapy of Opdivo
  • Table 145: Average Cost of Therapy of Yervoy + Opdivo
  • Table 146: Average Cost of Therapy of Atezolizumab
  • Table 147: Average Cost of Therapy of Avelumab
  • Table 148: Average Cost of Therapy of Cometriq
  • Table 149: Average Cost of Therapy of Lenvima
  • Table 150: Average Cost of Therapy of tivozanib
  • Table 151: Average Cost of Therapy of AGS-003
  • Table 152: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013
  • Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013
  • Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages ≥20 Years, N, 2013
  • Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 7: Treatment Algorithm for RCC
  • Figure 8: RCC - Phase III Pipeline, 2013-2023
  • Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in RCC, 2013-2023
  • Figure 10: Opdivo's Development in RCC
  • Figure 11: Clinical and Commercial Positioning of Opdivo
  • Figure 12: Atezolizumab's Development in RCC
  • Figure 13: Clinical and Commercial Positioning of Atezolizumab
  • Figure 14: Cometriq's Development in RCC
  • Figure 15: Clinical and Commercial Positioning of Cometriq
  • Figure 16: AGS-003's Development in RCC
  • Figure 17: Clinical and Commercial Positioning of AGS-003
  • Figure 18: Tivozanib's Development in RCC
  • Figure 19: Clinical and Commercial Positioning of Tivozanib
  • Figure 20: Lenvima's Development in RCC
  • Figure 21: Clinical and Commercial Positioning of Lenvima
  • Figure 22: Avelumab's Development in RCC
  • Figure 23: Clinical and Commercial Positioning of Avelumab
  • Figure 24: Global Sales of Branded Products for aRCC by Company, 2013-2023
  • Figure 25: Company Portfolio Gap Analysis in RCC, 2013-2023
  • Figure 26: Pfizer SWOT Analysis in RCC, 2014
  • Figure 27: Novartis SWOT Analysis in RCC, 2014
  • Figure 28: Bayer SWOT Analysis in RCC, 2014
  • Figure 29: Roche SWOT Analysis in RCC, 2014
  • Figure 30: Bristol-Myers Squibb SWOT Analysis in RCC, 2014
  • Figure 31: Merck & Co SWOT Analysis in RCC, 2014
  • Figure 32: Exelexis SWOT Analysis in RCC, 2014
  • Figure 33: Eisai SWOT Analysis in RCC, 2014
  • Figure 34: AVEO Oncology SWOT Analysis in RCC, 2014
  • Figure 35: Argos Therapeutics SWOT Analysis in RCC, 2014
  • Figure 36: Global Sales for aRCC by Region, 2013-2023
  • Figure 37: Global sales for aRCC by Class, 2013-2023
  • Figure 38: Global Sales for aRCC by Brand, 2013-2023
  • Figure 39: Sales for aRCC in the US by Class, 2013-2023
  • Figure 40: Sales for aRCC in the US by Brand, 2013-2023
  • Figure 41: Sales for aRCC in the 5EU by Class, 2013-2023
  • Figure 42: Sales for aRCC in 5EU by Brand, 2013-2023
  • Figure 43: Sales for aRCC in the Japan by Class, 2013-2023
  • Figure 44: Sales for aRCC in Japan by Brand, 2013-2023
  • Figure 45: Sales for aRCC in the China by Class, 2013-2023
  • Figure 46: Sales for aRCC in China by Brand, 2013-2023
Back to Top